Loading cancer entity…
Loading cancer entity…
Clinical trials
56 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05712356 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors(BOLSTER) | completed | Phase 2 | 66 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 |
| clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT02375880 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | completed | Phase 1 | 51 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04740164 | A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP | completed | N/A | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04072445 | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | completed | Phase 1 | 79 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT02649712 | Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction | completed | N/A | 72 | Xuzhou Central HospitalOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT00361231 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01267344 | A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC(BTC) | completed | Phase 2 | 122 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00238212 | S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials